New Canadian Rule Allows Rolling Data Submissions For COVID-19 Drugs, Vaccines
Enabling Timely Access To Novel Products Is Key Focus
The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.
